Research programme: anti-ganglioside GD2 monoclonal antibodies - BioWa

Drug Profile

Research programme: anti-ganglioside GD2 monoclonal antibodies - BioWa

Alternative Names: BIW-8137; KM-8138; POTELLIGENT-GD2

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioWa
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 03 Mar 2004 Anti-ganglioside GD-2 monoclonal antibody is available for licensing in Europe, North America and South America (http://www.biowa.com)
  • 11 Aug 2003 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top